Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | KDM4A | O75164 | 12/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 12/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KDM5A | P29375 | 1/20 | 0.49 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.49 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.49 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.49 |
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PAM | P19021 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25935555 | 1.00 | DNM1 (0.62) | DNM1CYP1A2KDM4AKDM4CALDH1A1 | |
| SCHEMBL10085306 | 0.98 | DNM1 (0.59) | DNM1CYP1A2KDM4AKDM4CALDH1A1 | |
| SCHEMBL23074569 | 0.94 | DNM1 (0.57) | DNM1CYP1A2KDM4AKDM4CALDH1A1 | |
| SCHEMBL4618714 | 0.92 | CYP1A2 (0.57) | DNM1CYP1A2ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL4002079 | 0.91 | DNM1 (0.57) | DNM1CYP1A2KDM4AKDM4CALDH1A1 | |
| SCHEMBL31325278 | 0.88 | CYP1A2 (0.57) | DNM1CYP1A2KDM4AKDM4CALDH1A1 | |
| SCHEMBL31357603 | 0.88 | CYP1A2 (0.57) | DNM1CYP1A2KDM4AKDM4CALDH1A1 | |
| SCHEMBL15156012 | 0.86 | DNM1 (0.49) | DNM1CYP1A2KDM4AKDM4CALDH1A1 | |
| SCHEMBL15155289 | 0.86 | DNM1 (0.49) | DNM1CYP1A2KDM4AKDM4CALDH1A1 | |
| SCHEMBL15155540 | 0.86 | DNM1 (0.49) | DNM1CYP1A2KDM4AKDM4CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034571-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2025-01-30 | — | — | US | disclosed |
| US-12129467-B2 | Non-liposomal systems for nucleic acid delivery | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-10-29 | — | — | US | disclosed |
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-06 | — | — | US | disclosed |
| US-20240035030-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-01 | — | — | US | disclosed |
| US-11718852-B2 | Non-liposomal systems for nucleic acid delivery | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-08 | — | — | US | disclosed |
| US-11718852-B2 | Non-liposomal systems for nucleic acid delivery | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-08 | — | — | US | disclosed |
| US-11718852-B2 | Non-liposomal systems for nucleic acid delivery | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-08 | — | — | US | disclosed |
| US-20210207140-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-07-08 | — | — | US | disclosed |
| US-20210207140-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-07-08 | — | — | US | disclosed |
| EP-2569276-B1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2021-02-24 | — | — | EP | disclosed |
| WO-2011141705-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-11-17 | — | — | WO | disclosed |
| WO-2010141833-A2 | VITAL FLUOROCHROME CONJUGATES AND METHODS OF USE | THE GENERAL HOSPITAL CORPORATION (US) | 2010-12-09 | — | — | WO | disclosed |
| EP-0988283-A2 | PEROXYACIDS | UNILEVER PLC (GB) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998056760-A1 | PEROXYACIDS | UNILEVER PLC (GB) | 1998-12-17 | — | — | WO | disclosed |
| EP-0021496-B1 | SYNTHESIS OF LONG-CHAIN ALKANES HAVING TERMINAL FUNCTIONALITY | THE PROCTER & GAMBLE COMPANY (US) | 1983-05-18 | — | — | EP | disclosed |
| US-4366101-A | Synthesis of long-chain alkanes having terminal functionality | THE PROCTER & GAMBLE COMPANY (US) | 1982-12-28 | — | — | US | disclosed |
| US-4287174-A | CONTAINING A QUATERNARY AMMONIUM CARBOXY ZWITTERIONIC COMPOUND AND AN ANTACID | THE PROCTOR & GAMBLE COMPANY (US) | 1981-09-01 | — | — | US | disclosed |
| US-4268697-A | Synthesis of long-chain alkanes having terminal functionality | THE PROCTER & GAMBLE COMPANY (US) | 1981-05-19 | — | — | US | disclosed |
| EP-0021496-A1 | Synthesis of long-chain alkanes having terminal functionality | THE PROCTER & GAMBLE COMPANY (US) | 1981-01-07 | — | — | EP | disclosed |
| EP-0004686-A2 | Anti-ulcer composition | THE PROCTER & GAMBLE COMPANY (US) | 1979-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | DNM1 239/4885CYP1A2 4876/4885KDM4A 3099/4885 |
| US-20250034571-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | DNM1 239/4885CYP1A2 4876/4885KDM4A 3099/4885 |
| US-20210207140-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | DNM1 239/4885CYP1A2 4876/4885KDM4A 3099/4885 |
| US-20240035030-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | DNM1 239/4885CYP1A2 4876/4885KDM4A 3099/4885 |
| US-12129467-B2 | Non-liposomal systems for nucleic acid delivery | SNRPE, NPC1L1, LIPA | DNM1 239/4885CYP1A2 4876/4885KDM4A 3099/4885 |
| US-11718852-B2 | Non-liposomal systems for nucleic acid delivery | SNRPE, NPC1L1, LIPA | DNM1 239/4885CYP1A2 4876/4885KDM4A 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.